Potential drugs for early Alzheimer's disease:Donanemab injection
Donanemab is a novel anti-amyloid antibody medication that is primarily used to treat early-stage symptomatic Alzheimer's disease.Clinical investigations have demonstrated that it modulates issues with cognitive function and everyday functioning.Preclinical research has discovered that it reduces amyloid deposition in the hippocampus and cortical layers of the brain.To better comprehend cutting-edge novel medications,this article examines the latest research on donanemab.